REGENXBIO

Associate Director, Regulatory Affairs

REGENXBIO  •  $160k - $218k/yr  •  Remote  •  4 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

The Opportunity

As Associate Director, Regulatory Affairs, you'll lead global regulatory strategy for a therapeutic area from early development through marketing authorization - translating complex requirements into clear paths forward, shaping health authority interactions, and partnering across functions to keep programs moving.

How You’ll Contribute

  • Set and drive global regulatory strategy from early Health Authority interactions through BLA/MAA registration.
  • Lead critical submission activities and regulatory writing, including pre-IND, orphan/paediatric investigation plan (PIP), Scientific Advice, End-of-Phase I/II, and pre-BLA/MAA meeting materials.
  • Be a strategic regulatory partner across development, commercialization, and lifecycle management for a therapeutic area.
  • Bring a forward-looking regulatory perspective to potential new products, working cross-functionally to develop innovative strategies.
  • Support commercial activities with regulatory guidance on labeling and promotional materials.
  • Bring expert regulatory insight and market interpretation to global development programs.
  • Work across R&D, Quality, Manufacturing, Supply Chain, Medical Affairs, Pharmacovigilance, and Regulatory Affairs to deliver high-quality dossiers and materials aligned with business priorities.
  • Partner with regional experts in the EU, Japan, and other markets to shape ex-US strategies and lead interactions with local regulatory agencies.
  • Represent REGENXBIO with industry teams, trade associations, and professional organizations.
  • Lead and develop one or more team members through hiring, training, clear expectations, coaching, and ongoing development.
  • Travel up to 15% as required.

What You’ll Bring

We are looking for someone who thrives in a collaborative, patient-focused environment and brings:

  • A bachelor's degree; an advanced degree in biological sciences is preferred.
  • 6-8 years of Regulatory Affairs experience, including product approval/launch, plus deep knowledge of one or more therapeutic areas.
  • Experience in biologics, orphan diseases, or CNS development is preferred.
  • A track record of resolving complex global regulatory issues.
  • Hands-on experience preparing high-quality FDA/EMA submission documentation and Health Authority meeting materials.
  • Strong written and verbal communication skills and the ability to build trusted relationships with internal stakeholders, external partners, and health authorities.
  • A resourceful, collaborative style - and the ability to be equally effective working independently.
  • Proactive, creative problem-solving and strong decision-making skills.

What You Can Expect

At REGENXBIO, we're committed to fostering an environment where people can do meaningful work, grow professionally, and make an impact. Our core values – trust, accountability, perseverance, and innovation – drive everything we do.

We offer a comprehensive and competitive benefit & compensation package which includes market-competitive salaries, an annual bonus program, education assistance, paid caregiver leave, retirement plan with employer match, stock options at all levels, summer hours and more! The estimated compensation range for this role is $160,000 to $218,000 annually. The actual salary offered to the final candidate depends on a number of factors such as relevant work experience, skills, education, and years of experience.

REGENXBIO

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.

Industry
Biotech & Life Sciences
Company Size
201-500 employees
Headquarters
Rockville, Maryland
Year Founded
2008
Social Media